on the date indicated above, I deposited this paper with identified attachments and/or fee with I hereby certify the U.S. Postal Service and that it was addressed for delivery to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 by "First Class Mail to Addressee" service.

Kim Blum Name (Print) Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: Akikuni YAGITA)	Examiner: Unassigned
Application No.: 10/528,509)	Group Art Unit: Unassigned
Filed: March 18, 2005)	Confirmation No.: Unassigned
Docket No.: 3190-077)	Customer No.: 33432

For: IMMUNOTHERAPEUTIC AGENT FOR CANCER

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR 1.97(b) and (c)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

August 29, 2005

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-SB-08. Pursuant to the current United States Patent and Trademark Office rules, no copies of U.S. Patents/Patent Application Publications are provided.

This Information Disclosure Statement is being submitted after expiration of the threemonth period following filing of the above-captioned application, but before an Office Action on the merits and before any Final Office Action or Notice of Allowance.

Should a first Office Action cross in the mail with the filing of this Information Disclosure statement, then applicants respectfully petition under 37 C.F.R.§ 1.97(c) to consider the documents set forth in the Information Disclosure Statement.

The undersigned hereby certifies that each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

In lieu of English translations of the non-English documents, the International Search Report which cited the non-English documents is enclosed for the relevance of these documents.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. *See* 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-SB-08 be made of record therein and appear on the first page of any patent to issue therefrom.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in this application and applicant determines that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application. Information Disclosure ment U.S. Patent Application 10/528,509

It is believed that no fee is required to make this a complete and timely filing. However, if it is determined that a petition or fee is required, the Commissioner is hereby authorized to charge any fee associated with this statement to our Deposit Account No. 50-0925 and please consider this a petition.

Respectfully submitted,

Luke A. Kilyk

Reg. No. 33,251

Atty. Docket No.: 3190-077

KILYK & BOWERSOX, P.L.L.C.

53 A East Lee Street Warrenton, VA 20186 Tel: (540) 428-1701

Tel: (540) 428-1701 Fax: (540) 428-1720

Enclosures: Form PTO-SB-08 and 10 documents

Approve U.S. Patent and Trademark

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO Application Number 10/528,509 Filing Date March 18, 2005 INFORMATION DISCLOSURE First Named Inventor Akikuni YAGITA STATEMENT BY APPLICANT Art Unit Unassigned (use as many sheets as necessary) **Examiner Name** Unassigned of Sheet Attorney Docket Number 3190-077

				U.S. F	PATENT DO	CUMENTS				
xaminer	Cite	Document Number	Publication			Name of Patentee or		Pages, Columns, Lines, Where		
nitials*	No.1	Number - Kind Code ² (if known)	MM-DD-Y	YYY	,	Applicant of Cite	ed Document	Relevant Passages or Relevant Figures Appear		
	t —	US-6,238,660 B1	5/29/2001		Yaqita			Tigaros, podi		
	T	US-6,464,981 B2	10/15/2002		Yagita			-		
		US-		`						
	Ì	US-								
		US-								
		US-								
	<u> </u>	US-								
	L.	US-								
	<u> </u>	US-						•		
		US-			ļ					
		US-					·			
	ļ	US-								
		US-								
	<u></u>	US-					 			
				REIG	N PATENT	DOCUMEN	TS			
	L	Foreign Patent Docume	nt .	Publication Date		Name of Pa	tentee or Applicant of	Pages, Columns, Lines,		
Examiner Initials*	Cite No. ¹	Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)		MM-DD-YYYY		Cited Document		Where Relevant Passages or Relevant Figures Appear	⊤ ⁵	
		EP 0 844 002 A1		5/27	/1998	Akikuni Y	agita		See US 6,238,660 B1	
		JP 2001-081047 A		3/27	/2001	Akikuni Yagita Orient Cancer Therapy Co., Ltd.			JPO Computer Translation	
		EP 1 250 934 A1		10/2	3/2002					
		WO 01/82935 A1 (first page	ge)	Orient Car 11/8/2001 Co., Ltd.		ncer Therapy		See US 6,464,981		
		JP 10-14753		6/2/1	998	Yakida Ak Kigyo: KK	ikuni Seishin NOF Corp.		JPO Computer Translation	
							<u></u>			
		_								
							-			
Examine	er						Date	<u> </u>	· · · ·	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. There Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (05-03) e through 04/30/2003. OMB 0651-0031 ; U.S. DEPARTMENT OF COMMERCE

Approve U.S. Patent and Trademark G.Je; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	O hall to for farm 44404/DTO		Complete if Known		
Substitute for form 1449A/PTO		Application Number	10/528,509		
1811		DICCI O	NUDE	Filing Date	March 18, 2005
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				First Named Inventor	Akikuni YAGITA
				Art Unit	Unassigned
(use as many sheets as necessary)		Examiner Name	Unassigned		
Sheet	2	of	2	Attorney Docket Number	3190-077

•		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city, and/or country where published.	T²
		YAGITA et al., "Novel Immunotherapy Using an Angiogenesis Inhibitor and Human Natural (Hn) IL-12 Inducers Particularly on the Participation of NKT Cells," BIOTHERAPY, Vol. 14, No. 5, May 2000, pgs. 433-	
		439 (Summary of article in English). KAII et al., "Kokei gan ni tai suru bunshi hyouteki chiryou. I. Kobunshi busshitsu 1. 'Yyrosine kinase'	
		sogaizai (1) ZK1839," KETSUEKI MENEKI SHUYO, Vol. 7, No. 3, July 20, 2002, pgs. 13-22 (in Japanese). TAKAYAMA et al., "Kokei gan ni tai suru bunshi hyouteki chiryou. I. Kobunshi busshitsu 1, 'Tyrosine kinase' sogaizai (2) STI-571 (Imatinib Mesylate) wo mochiita GIST no chiryou," KETSUEKI MENEKI SHUYO, Vol. 7, No. 3, July 20, 2002, pgs. 23-27 (in Japanese).	
	-	ARASE, "NKT saibou no 'cytokine' sansei to sono igi," Saishin Igaku, Vol. 55, No. 4, April 2000, pgs. 818-823 (in Japanese).	·
		International Preliminary Report on Patentability for PCT/JP2003/011895 dated July 29, 2004 (date of mailing: June 30, 2005).	
			·
Examine Signatur		Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.